[Antithrombotic effects of molsidomine alone and in combination with other antithrombotic agents in a thrombosis model of the microcirculation of the rat].
The antithrombotic effect of Molsidomin and other different antithrombotic agents have been investigated alone and in combinations in a thrombosis model in rats in which mesenteric vessels with a diameter of 20-30 microns were injured by defined argon laser lesions. In this animal thrombosis model all agents showed a significant and dose-dependent antithrombotic effect. A strong additive effect was observed when Molsidomin was infused together with Cicaprost. A similar additive effect was observed after administration Molsidomin together with heparins. The combination of a minimal effective dose of Molsidomin with Aprosulate also had a significant additive effect. After application of Molsidomin together with a TXA2 receptor antagonists a slight additive antithrombotic effect was observed.
Giedrojc
J
J
Abteilung für Angiologie, Zentrum der Inneren Medizin, J.W. Goethe-Universität, Frankfurt/Main.
Weichert
W
W
Breddin
H K
HK
D000818:Animals; D004187:Disaccharides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology; D007262:Infusions, Intravenous; D008641:Mesenteric Vascular Occlusion / Q000097:blood*; D008833:Microcirculation / Q000187:drug effects / Q000502:physiology; D008981:Molsidomine / Q000494:pharmacology*; D009569:Nitric Oxide / Q000502:physiology; D010648:Phenylacetates / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology; D013927:Thrombosis / Q000097:blood*
D004187:Disaccharides; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010648:Phenylacetates; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D009569:Nitric Oxide; D006493:Heparin; D008981:Molsidomine; D011464:Epoprostenol; C043867:cicaprost; C051762:daltroban; C069690:aprosulate
Antithrombotische Wirkungen von Molsidomin allein und in Kombination mit anderen Antithrombotika an einem Thrombosemodell in der Mikrozirkulation der Ratte.